Premal H. Thaker, MD, MS

Premal H. Thaker, MD,MS is the David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology; Director, Gynecological Oncology Clinical Research; Interim Chief, Division of Gynecologic Oncology.

Articles by Premal H. Thaker, MD, MS

Unmet Needs in Second-Line Therapy for Metastatic Cervical Cancer

ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS

November 18th 2021

Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.

Metastatic Cervical Cancer: Interpreting Data From KEYNOTE-826

ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu Tewari, MD,Premal H. Thaker, MD, MS

November 18th 2021

Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.

KEYNOTE-826: Immune Checkpoint Inhibition in Metastatic Cervical Cancer

ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS

November 10th 2021

Considerations for the KEYNOTE-826 trial, which tested pembrolizumab in combination with chemotherapy in patients with metastatic cervical cancer.

Chemotherapy and Antiangiogenesis Therapy in Metastatic Cervical Cancer

ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS

November 10th 2021

Looking at the current treatment landscape in metastatic cervical cancer, experts consider the role of frontline chemotherapy and antiangiogenesis therapy.

Ongoing Clinical Trials in Locally Advanced Cervical Cancer

ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS

November 3rd 2021

Closing out their discussion on locally advanced cervical cancer, panelists discuss ongoing clinical trials and the potential of the involved novel therapies.

Locally Advanced Cervical Cancer: Interpreting the OUTBACK Trial

ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS

November 3rd 2021

Considerations for the negative results of the OUTBACK trial, which tested adjuvant chemotherapy in locally advanced cervical cancer.

Locally Advanced Cervical Cancer: Surgery and Standard of Care Therapy

ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS

October 27th 2021

Focusing on locally advanced cervical cancer, experts elucidate the role of surgery and standard of care therapy.

What is the Current Role of Biomarker Testing in Cervical Cancer?

ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS

October 27th 2021

The panel reflects on the current, optimal use of biomarker testing to guide the management of cervical cancer.

Role of HPV Vaccination and Screening to Prevent Cervical Cancer

ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS

October 20th 2021

A comprehensive review of the current paradigm for HPV vaccination and screening to prevent cervical cancer.

Understanding the Biology and Staging of Cervical Cancer

ByBradley J. Monk, MD, FACOG, FACS,Warner K. Huh, MD, UAB,Bhavana Pothuri, MD,Krishnansu S. Tewari, MD,Premal H. Thaker, MD, MS

October 20th 2021

Experts provide a brief overview of cervical cancer, focusing on the driving biology and FIGO staging system.

Dr. Thaker on EGEN-001 Combined With Doxorubicin for Ovarian Cancer

ByPremal H. Thaker, MD, MS

July 28th 2015

Premal H. Thaker, MD, MS, discusses a phase I study examining the combination of EGEN-001 and doxorubicin for the treatment of patients with platinum-resistant ovarian cancer.

Premal H. Thaker, MD, MS

Articles by Premal H. Thaker, MD, MS

Unmet Needs in Second-Line Therapy for Metastatic Cervical Cancer

Metastatic Cervical Cancer: Interpreting Data From KEYNOTE-826

KEYNOTE-826: Immune Checkpoint Inhibition in Metastatic Cervical Cancer

Chemotherapy and Antiangiogenesis Therapy in Metastatic Cervical Cancer

Ongoing Clinical Trials in Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer: Interpreting the OUTBACK Trial

Locally Advanced Cervical Cancer: Surgery and Standard of Care Therapy

What is the Current Role of Biomarker Testing in Cervical Cancer?

Role of HPV Vaccination and Screening to Prevent Cervical Cancer

Understanding the Biology and Staging of Cervical Cancer

Dr. Thaker on EGEN-001 Combined With Doxorubicin for Ovarian Cancer

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma